Canada - English - Health Canada

pro doc limitee - sitagliptin (sitagliptin malate) - tablet - 25mg - sitagliptin (sitagliptin malate) 25mg

Canada - English - Health Canada

pro doc limitee - sitagliptin (sitagliptin malate) - tablet - 50mg - sitagliptin (sitagliptin malate) 50mg

Canada - English - Health Canada

pro doc limitee - sitagliptin (sitagliptin malate) - tablet - 100mg - sitagliptin (sitagliptin malate) 100mg

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sitagliptin hydrochloride monohydrate, quantity: 109 mg (equivalent: sitagliptin, qty 100 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate dihydrate; sodium stearylfumarate; povidone; magnesium stearate; croscarmellose sodium; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - pharmacor sitagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:,- monotherapy when metformin is considered inappropriate due to intolerance; or,- in combination with other anti-hyperglycaemic agents, including insulin,[see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sitagliptin hydrochloride monohydrate, quantity: 109 mg (equivalent: sitagliptin, qty 100 mg) - tablet, film coated - excipient ingredients: sodium stearylfumarate; magnesium stearate; povidone; croscarmellose sodium; calcium hydrogen phosphate dihydrate; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - pharmacor sitagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:,- monotherapy when metformin is considered inappropriate due to intolerance; or,- in combination with other anti-hyperglycaemic agents, including insulin,[see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

Canada - English - Health Canada

apotex inc - sitagliptin (sitagliptin phosphate monohydrate); metformin hydrochloride - tablet (extended-release) - 50mg; 500mg - sitagliptin (sitagliptin phosphate monohydrate) 50mg; metformin hydrochloride 500mg

Canada - English - Health Canada

apotex inc - sitagliptin (sitagliptin phosphate monohydrate); metformin hydrochloride - tablet (extended-release) - 50mg; 1000mg - sitagliptin (sitagliptin phosphate monohydrate) 50mg; metformin hydrochloride 1000mg

Canada - English - Health Canada

apotex inc - sitagliptin (sitagliptin phosphate monohydrate); metformin hydrochloride - tablet (extended-release) - 100mg; 1000mg - sitagliptin (sitagliptin phosphate monohydrate) 100mg; metformin hydrochloride 1000mg

Canada - English - Health Canada

apotex inc - sitagliptin (sitagliptin malate); metformin hydrochloride - tablet - 50mg; 500mg - sitagliptin (sitagliptin malate) 50mg; metformin hydrochloride 500mg

Canada - English - Health Canada

apotex inc - sitagliptin (sitagliptin malate); metformin hydrochloride - tablet - 50mg; 850mg - sitagliptin (sitagliptin malate) 50mg; metformin hydrochloride 850mg